Description
Crystagen (also spelled Cristagen or Kristagen) is a short-chain peptide bioregulator in the Khavinson cytomedin / cytogen class — synthetic short peptides developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, proposed to function through tissue-specific gene expression modulation. Crystagen is described as a thymus / immune tissue-derived peptide bioregulator within this peptide family. The specific sequence reported in Russian academic sources varies — some describe Crystagen as a tetrapeptide preparation, others as a tripeptide — and the chemistry is less rigorously documented in mainstream Western scientific literature than the major characterized Khavinson peptides (Epithalon, Cortagen, Pinealon). The compound is investigated in preclinical research as a representative of the broader Khavinson short-peptide bioregulator class for tissue-specific peptide pharmacology and comparative SAR studies. Researchers working with this compound should verify the specific chemistry against the supplier’s Certificate of Analysis (COA) and rely on MS-verified molecular weight as the primary identity confirmation.
Benefits (Research Focus)
• Khavinson cytomedin research — studied as a representative compound for tissue-specific peptide bioregulator pharmacology
• Cellular gene expression — investigated for gene expression endpoints in cell culture research models
• Comparative SAR research — explored alongside other Khavinson short-peptide bioregulators for structure-activity studies
• Tissue-specific peptide signaling — examined as a “cytomedin” class compound for tissue-selective gene expression research
• Geroscience research — researched for cellular aging endpoints in research models
What Researchers Look At
• Gene expression panels in cell culture research models
• Comparative pharmacology versus characterized Khavinson peptides (Epithalon, Cortagen, Pinealon)
• Cellular proliferation and viability markers in research models
• Molecular weight characterization and MS-based identity verification
• Aged-tissue versus young-tissue model responses in comparative research
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 20 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Crystagen
• Synonyms: Cristagen; Kristagen; Khavinson-tradition thymus/immune peptide bioregulator
• Class: Short-chain peptide bioregulator; Khavinson-tradition cytomedin / cytogen class
• Reported sequence: Varies across sources — some describe as KEDG tetrapeptide, others as tripeptide. Verify against batch COA.
• Origin: Khavinson-tradition peptide bioregulator
• Molecular Weight: Low molecular weight peptide (verify against batch COA — MS data should clarify whether tripeptide or tetrapeptide chemistry)
• CAS: Not formally assigned in mainstream chemical databases (peptide bioregulator class)
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• [COA links for the Crystagen 20mg batch to be added once Janoshik testing is complete]
